secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001558370-21-013985
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q3 net loss widens to $21.1M; cash $243.6M; IND filed for ATI-2138
--------------------------------------------------------------------------

- Net loss Q3 2021: $21.1M vs $10.7M in Q3 2020; revenue $1.7M vs $1.4M.
- Cash, cash equivalents and marketable securities of $243.6M as of Sep 30, 2021; runway through end of 2024.
- IND submitted in Oct 2021 for ATI-2138, an oral ITK/TXK/JAK3 inhibitor for psoriasis.
- Zunsemetinib (ATI-450) Phase 2b in RA planned Q4 2021; Phase 2 trials in psoriatic arthritis and hidradenitis suppurativa planned.
- Kamil Ali-Jackson, Chief Legal Officer and Co-Founder, retiring effective Jan 3, 2022; severance includes salary, bonus, vesting acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837021013985/0001558370-21-013985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837021013985/acrs-20211101x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-013985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer